Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6SY9X
|
|||
| Drug Name |
Aficamten
|
|||
| Synonyms |
Aficamten; 2364554-48-1; Aficamten [INN]; Aficamten [USAN]; CK-3773274; B1I77MH6K1; Aficamten [USAN:INN]; UNII-B1I77MH6K1; CHEMBL4847050; WHO 11544; 1H-Pyrazole-4-carboxamide, N-((1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-; N-((1R)-5-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide; N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide; SCHEMBL21179170; GTPL11524; EX-A5344; BDBM50575173; CK-274; AKOS040759755; MS-25122; CK3773274; HY-139465; CK-3773274;CK-274; CS-0202223; (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Hypertrophic cardiomyopathy [ICD-11: BC43.1] | Phase 3 | [1] | |
| Company |
Cytokinetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H19N5O2
|
|||
| Canonical SMILES |
CCC1=NC(=NO1)C2=CC3=C(C=C2)C(CC3)NC(=O)C4=CN(N=C4)C
|
|||
| InChI |
InChI=1S/C18H19N5O2/c1-3-16-21-17(22-25-16)12-4-6-14-11(8-12)5-7-15(14)20-18(24)13-9-19-23(2)10-13/h4,6,8-10,15H,3,5,7H2,1-2H3,(H,20,24)/t15-/m1/s1
|
|||
| InChIKey |
IOVAZWDIRCRMTM-OAHLLOKOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cardiac myosin (MYBPC3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Hypertrophic cardiomyopathy (HCM) | |||
| Dilated cardiomyopathy | ||||
| Reactome | Striated Muscle Contraction | |||
| WikiPathways | Striated Muscle Contraction | |||
| Muscle contraction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05767346) A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. U.S.National Institutes of Health. | |||
| REF 2 | Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 Oct 14;64(19):14142-14152. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.